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W
ith an improved understanding of the molecular landscapes of ovarian, uterine, and cervical cancer, an interest in targeted therapies has emerged. [1] [2] [3] [4] This molecular granularity has translated into U.S. Food and Drug Administra on (FDA) approvals of the an angiogenic agent bevacizumab and of the PARP inhibitors (niraparib, rucaparib, olaparib), a er a nearly 10-year interval which saw limited progress in pa ents suff ering from recurrent cervical and ovarian cancer.
In an eff ort to expand on the above, inves gators have turned their attention beyond traditional genomic mutations, exploring the role of the epigenome on cancer progression, in an attempt to identify novel therapeutic strategies. Epigene cs is defi ned as changes in gene expression that are not due to altera ons in DNA sequence. 5 The principal epigene c changes iden fi ed, and studied, to date include the following: (1) DNA methyla on, (2) histone modifi ca on, and (3) microRNA (miRNA) inhibi on. 6 This epigene c reprograming of gene expression has been clearly iden fi ed as a driver in malignant transforma on and cancer propaga on. 7 Tradi onally, malignant transforma on is thought to arise from the ac va on of oncogenes or the inac va on of tumor suppressor genes via germline or soma c mutaons. More recently, changes in the epigenome have been iden fi ed, which contribute to the ini a on and progression of cancer. Approximately 40% of genes harbor DNA promotor regions rich in cytosines that precede guanines (CpGs), which, when methylated, result in transcrip onal repression. This process, catalyzed by DNA methyltransferases (DNMTs), may occur in the promotor regions of tumorsuppressor genes, resul ng in oncogenic transforma on. This paradigm has been well described for the retinoblastoma (Rb), p16, hMLH1, and BRCA1 tumor-suppressor genes. [8] [9] [10] [11] [12] In humans, the three known DNMTs include DN-MTA1, DNMT3A, and DNAMT3B. DNMT1 is responsible for maintaining hemimethyla on of DNA during replica on, whereas DNMT3A and DNMT3B can catalyze de novo DNA methyla on. 13 Beyond DNA CpG island methyla on, epigene c regula on may occur via histone modifi ca on. Histones are a group of proteins responsible for DNA packaging and are amenable to modifi ca on on their N-terminal residue. Mulple complex combina ons have been described, including methyla on, acetyla on, and phosphoryla on occurring at lysine, arginine, or serine residues.
14 Importantly, acetyla on and methyla on of histones can result in mul ple downstream eff ects aff ec ng transcrip on, DNA replicaon, and repair, as well as chromosome organiza on. 6 Histone acetyla on is generally associated with transcrip onal ac va on, whereas the eff ect of methyla on varies and depends on the amino acid residue and its loca on. In an analogous manner to DNA promoter methyla on, histone modifi ca on via hypoacetyla on, and methyla on of lysine-9 on histone H3 or lysine-27, can lead to transcrip onal repression. Conversely, acetylation of histone H3 and H4
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OVERVIEW
The care of pa ents with advanced-stage or recurrent endometrial, ovarian, and cervical cancer remains clinically challenging. Despite the iden fi ca on of novel therapeu cs and advancements in suppor ve care, survival outcomes have been rela vely unchanged over the past decade. In addi on to established genomic altera ons and the contribu ons of the tumor microenvironment to cancer progression, epigene c mechanisms have emerged as important contributors to gynecologic cancer progression. DNA methyla on, histone modifi ca on, and noncoding RNA expression may be important contributors to disease ini a on and progression and may represent novel therapeu c targets. This ar cle reviews the epigene c landscape of endometrial, ovarian, and cervical cancer, describing the state of the science and discussing poten al clinical applica ons. To date, the role of epigene c drugs in the treatment of gynecologic cancers remains unclear, although con nued progress may inform future treatment modali es.
and methyla on of lysine-4 residue of histone H3 have been associated with gene ac va on. 15 These processes are mediated by a family of proteins, including histone acetyltransferases, histone deacetylase (HDAC), histone demethylases, and histone methyltransferases.
More recently, the infl uence of noncoding RNAs, including miRNA, on transcrip onal regula on has been described. These small 22-nucleo de sequences regulate gene expression via binding at the 3ʹ untranslated region, resul ng in the formation of RNA-induced silencing complexes, with inhibi on of transla on or RNA destabiliza on. 16 Evalua on of both normal and cancer ssue specimens suggests that miRNA downregula on is associated with tumorigenesis and that miRNA may serve a tumor suppressor func on. As an example, the downregula on of the let-7 family of miRNAs has been linked to lung cancer progression and is thought to be mediated by RAS oncogene ac va on. 17 The paradigm of epigenomic therapeu cs has been most extensively examined in the hematologic arena, in which the FDA has approved six agents as an neoplas c drugs: vorinostat (HDAC inhibitor), romidepsin (HDAC inhibitor), 5-azacy dine (DNA methyltransferase inhibitor), decitabine (DNA methyltransferase inhibitor), and ruxoli nib (JAK1/2 inhibitor).
In patients with gynecologic malignancies, epigenetic silencing has been hypothesized to be a driver of cancer progression, with diff eren al methyla on profi les in endometrial, ovarian, and cervical cancer specimens. 18 Given the substan al unmet clinical need, transla onal scien sts and clinical trialists are exploring the implica ons of the epigenome and the therapeu c effi cacy of novel epigene c agents on oncologic outcomes in pa ents with gynecologic cancer.
ENDOMETRIAL CANCER
Endometrial cancer con nues to be the most common gynecologic malignancy in the United States and is the only cancer of the female genital tract with a rising incidence and mortality. 19 In 2018, it is es mated that there will be 62,230 new cases and 11,350 deaths. 20 Despite the excellent prognosis in pa ents with early-stage disease, those with metasta c or recurrent endometrial cancer have limited therapeu c op ons. Since the comple on of Gynecologic Oncology Group (GOG) protocol 177, which explored the triplet regimen of paclitaxel, doxorubicin, and cispla n in pa ents with advanced-stage and recurrent endometrial cancer, there have been limited therapeu c advancements. 21 GOG protocol 209 was a subsequent phase III clinical trial comparing the combination regimen of carboplatin plus paclitaxel to the combina on of paclitaxel, doxorubicin, and cispla n. This study enrolled more than 1,300 pa ents and demonstrated less toxicity and a noninferior progressionfree survival and overall survival with the doublet regimen of carbopla n plus paclitaxel. Furthermore, second-line chemotherapy op ons for endometrial cancer are notably less eff ec ve, with Megace (Bristol-Myers Squibb) being the only FDA-approved agent in this se ng.
Growing evidence suggests that epigene c altera on, in the form of aberrant DNA methyla on, is a widespread and early altera on in endometrial cancer progression that aff ects the expression of numerous important genes. Molecular analysis of endometrial tumorigenesis in 110 cancer specimens and 62 controls iden fi ed promotor hypermethyla on, and transcrip onal repression, in 24 tumor suppressor genes, with progressive methylation from simple hyperplasia to complex hyperplasia and ul mately carcinoma. 22 Furthermore, in DNA mismatch repair (MMR) gene mutaon carriers, MMR and methyla on defects were iden fi ed more than 10 years before the diagnosis of endometrial cancer. 22 To date, DNA promoter methyla on has been idenfi ed in several gene targets in endometrial cancer, potenally contribu ng to carcinogenesis (Table 1) . Cell cycle regula on, cellular adhesions, apoptosis
PRACTICAL APPLICATIONS
P53
Regulates cellular prolifera on, apoptosis induc on, DNA repair
PTEN
Phosphatase and tensin homolog
Regulates cellular prolifera on and apoptosis
CDH1
E-Cadherin Epithelial cell adhesion
ERα
Estrogen receptor alpha
Regula on of prolifera on
PR-B Progesterone receptor
Regula on of prolifera on It is well established that germline muta ons in DNA mismatch repair genes (hMLH1, hMSH2, hMSH3, hMSH6, and hPMS2) result in Lynch syndrome, with an increased risk for endometrial cancer. 23 More recently, hMLH1 promoter hypermethyla on has been reported in up to 40% of endometrial cancer specimens, resul ng in transcrip onal repression and a microsatellite-high phenotype. 24 This fi nding is par cularly relevant given the recent success of immune checkpoint inhibi on in pa ents with MMR-defi cient, recurrent endometrial cancer. Building on ini al data published by Le and colleagues, 25 Fader and colleagues 26 presented an expanded cohort of pa ents with MMR-defi cient and recurrent or persistent endometrial cancer treated with single-agent treatment with pembrolizumab. All 10 pa ents had received at least one prior line of systemic chemotherapy and up to four previous regimens. The authors reported an overall response rate of 70% (95% CI, 21%-86%; seven pa ents), with two complete responses and fi ve par al responses. The disease control rate, or "clinical benefi t" rate (complete response + par al response + stable disease), was 80% (eight pa ents). The 12-month overall survival rate was 89%, and the median overall survival was not yet reached at me of repor ng. Importantly, microsatellite instability (MSI) status was determined by using standard-of-care MMR immunohistochemistry tes ng for hMLH1, hMSH2, hMSH6, and hPMS2. Pa ents lacking expression of DNA MMR proteins were classifi ed as MSI-high, consistent with prior studies repor ng concordance rates greater than 90% between MMR immunohistochemistry and MSI polymerase chain reac on. In the trial, hMLH1 promoter hypermethyla on was not evaluated in pa ents lacking immunohistochemistry expression of hMLH1 or hPMS2.
Most recently, a er review of pooled data from fi ve uncontrolled, open-label, mul cohort, mul center, single-arm trials, single-agent pembrolizumab was approved for the treatment of MMR-defi cient (MSI-high) solid tumors that progressed following prior therapy, with no alterna ve treatment op ons. This disease site-agnos c approval, issued by the FDA on May 23, 2017, was the fi rst of its kind, refl ec ng the clinical relevance of checkpoint inhibi on in patients with limited therapeutic options. Across all five trials, the effi cacy analysis showed an overall response rate (ORR) of 39.6% (95% CI, 31.7%-47.9%) with a complete response rate of 7.4% and a par al response rate of 32.2%. At the me of data cutoff , median dura on of response had not yet been reached (range, 1.6+ to 22.7+ months), with 78% of responding pa ents having responses of 6 months or longer. Of the 149 pa ents in the pooled analysis, 14 had recurrent endometrial cancer, with a reported ORR of 36% (dura on of response range, 4.2+ to 17.3+ months), surpassing historical controls in this pretreated pa ent popula on.
In the recurrent disease se ng, a variety of therapeu c approaches using various hormonal agents have been examined, with a clinical benefi t rate approaching 40%. 27 Hormonal therapy is appealing in this pa ent popula on, principally because of ease of administra on as well as the benefi cial therapeu c index. Despite robust preclinical and biologic ra onal for endocrine therapy, these agents are commonly eff ec ve for a brief period, with pa ents developing resistance and progressive disease. 27 It is hypothesized that resistance is a result of progesterone receptor downregula on and silencing of signal transduc on. This was exemplifi ed in GOG protocol 0211, a preopera ve window-of-opportunity trial in women with endometrial cancer. A er the diagnosis of biopsy-proved disease, women were enrolled to receive medroxyprogesterone acetate 21 to 24 days before surgery. The authors reported a 64% par al response rate and one complete response among 59 women. 28 Interes ngly, GOG-0211 illustrated a downregula on of progesterone receptor a er exposure to medroxyprogesterone. In preclinical models, progesterone receptor downregula on is thought to result from promoter CpG hypermethyla on and gene silencing.
The preceding results have since catalyzed the development and ac va on of NRG-GY011, a randomized surgical window pilot investigation of the relationship of shortterm medroxyprogesterone acetate therapy compared with medroxyprogesterone acetate plus en nostat on the morphologic, biochemical, and molecular changes in primary endometrioid adenocarcinoma of the uterine corpus. The selec on of en nostat, an HDAC inhibitor, in protocol design was driven by its oral formula on and ease of administra on, robust data sugges ng its effi cacy in upregula ng and maintaining progesterone receptor levels, and cellular diff eren a on. 29 The results of this trial may subsequently inform the u lity of a combinatorial approach, hormonal therapy plus epigene c modifi er, in pa ents with recurrent endometrial carcinoma.
In addi on to the above, the ARID1A gene has been idenfi ed as a frequently mutated tumor suppressor in several gynecologic malignancies.
30 ARID1A encodes the BAF250a protein, a member of the SWItch/sucrose nonfermentable (SWI/SNF) complex, par cipa ng in chroma n remodeling and transcrip onal regula on. 31 Aberra ons in chroma n remodeling have been iden fi ed in approximately 20% of all human cancers.
32 Specifi cally, the SWI/SNF complex is involved in ac va on or inhibi on of transcrip on and plays a crucial role in carcinogenesis. 30 More recently, studies have shown that ARID1A mutations are involved in carcinogenesis via the phospha dylinositol-3-kinase (PI3K)/protein kinase B (AKT) pathway, with resultant cellular prolifera on and inhibi on of apoptosis.
30
Gene c studies have revealed an evolu onarily conserved antagonis c rela onship between the SWI/SNF complex and polycomb group proteins. 33 The loss of SWI/SNF complex subunits (ARID1A, SMARCB1, and SMARA4) results in unopposed zeste homolog 2 (EZH2) ac vity, promo ng carcinogenesis, and oncogenic transforma on.
ARID1A muta ons have been iden fi ed in up to 47% of low-grade endometrioid endometrial carcinomas, 60% of high-grade endometrioid adenocarcinomas, 11% of serous adenocarcinomas, and up to 24% of carcinosarcomas. 30 An association between loss of ARID1A protein expression and activation of the PI3K/AKT pathway has also been detailed. Muta ons of PTEN and PIK3CA frequently occur in endometrial carcinomas with ARID1A muta on, and it is hypothesized that these ARID1A muta ons induce aberrant ac va on of the PI3K pathway. 30 Addi onally, inves gators have explored the possibility that ARID1A muta on may result in defec ve MMR, resul ng in MSI and greater tumor muta onal burden. A strong associa on between ARID1A loss and sporadic MSI is thought to result from epigene c silencing of MLH1.
34
Given the data outlined above, inves gators are looking to evaluate the ac vity of single-agent tazemetostat (an oral EZH2 inhibitor) in pa ents with recurrent endometrioid adenocarcinoma. This epigene c approach seeks to capitalize on the oncogenic addic on of ARID1A-mutated endometrial cancers on EZH2 activity. Translational endpoints will include BAF250a immunohistochemistry expression on tumor samples, as well as genomic sequencing of 467 other genes, including alternate components of the SWI/SNF pathway (e.g., ARID1B, ARID2, SMARCA4, SMARCB1, SMARCD1, and PBRM1).
OVARIAN CANCER
Epithelial ovarian cancer accounts for 25% of all malignancies aff ec ng the female genital tract and remains the most fatal gynecologic malignancy. In the United States, a projected 22,240 new cases will be diagnosed in 2018, with 14,070 deaths. 20 Advanced-stage epithelial ovarian cancer is managed with primary or interval surgical cytoreduc on and combina on pla num-and taxane-based chemotherapy. 35 In some centers, use of the intraperitoneal-intravenous drug delivery route has persisted despite confl ic ng clinical trial results. 36 Conversely, a weekly, dose-dense schedule for paclitaxel gained popularity a er an overall survival advantage was reported in a Japanese GOG clinical trial, with the more recent ICON-8 results once again ques oning this approach.
37, 38 Irrespec ve of cytotoxic regimen and mode of administra on, the greatest hurdles in the treatment of paents with advanced-stage ovarian cancer remains acquired drug resistance and selec on of pla num-resistant clones. 39 Thus, the development of ac ve, tolerable, noncytotoxic drugs has emerged as a priority in epithelial ovarian cancer research.
As discussed earlier, the evolu on of our understanding of the molecular landscape of ovarian cancer has facilitated drug development, with the recent FDA approval of three separate PARP inhibitors in the maintenance therapy and recurrent se ngs. These promising advances have addi onally promoted the inves ga on of alternate therapeu cs, including poten al epigene c targets. Perhaps the most notable epigene c changes iden fi ed in ovarian cancer are the methyla on, and silencing, of the tumor suppressors BRCA1 and hMLH1, both responsible for DNA damage repair. 40, 41 In a recent large case-control study of more than 5,000 women, BRCA1 promoter methyla on was iden fi ed more frequently in pa ents with ovarian cancer than controls (6.4% vs. 4 In an eff ort to improve clinical outcomes, inves gators have examined the eff ect of DNMT inhibitors on chemotherapy sensi vity in preclinical models, and the poten al for reversal of pla num and taxane resistance. 43, 44 Subsequently, in a phase I clinical trial, low-dose decitabine was given in combination with carboplatin in patients with recurrent, pla num-resistant ovarian cancer. 45 Decitabine was administered intravenously daily for 5 days, before carbopla n area under the curve of 5 on day 8 of a 28-day cycle. A standard 3 + 3 dose escala on design was used, with decitabine tested at two dose levels: 10 mg/m 2 (seven patients) or 20 mg/m 2 (three patients). Dose-limiting toxicity at the 20-mg/m 2 dose was grade 4 neutropenia (two pa ents), and no dose-limi ng toxici es were observed at 10 mg/m 2 . 45 Ten heavily pretreated pa ents were enrolled (median of fi ve prior lines of therapy), with nine comple ng at least one cycle of therapy. One complete response was observed, and three addi onal pa ents had stable disease for 6 months or more. Transla onal on-treatment assessment of methyla on using polymerase chain reac on demonstrated reduced global methyla on on days 8 and 15 when compared with day 1. 45 The biologic ac vity seen in this early phase I study prompted the assessment of alternate epigene c agents, specifi cally HDAC inhibitors, in pa ents with recurrent ovarian cancer. In a phase II clinical trial, Dizon and colleagues examined the activity of belinostat in combination with carboplatin in women with platinum-resistant, recurrent ovarian cancer. 46 A total of 27 eligible and evaluable women were enrolled in the trial and treated with 1,000 mg/m 2 of belinostat daily for 5 days with carbopla n area under the curve of 5 on day 3 of a 21-day cycle. The median number of cycles given was two (range, 1 to 10). One pa ent had a complete response and one had a par al response (due to lack of normaliza on of her Ca-125 level), for an ORR of 7.4% (95% CI, 0.9%-24.3%), resul ng in closure of the trial a er the fi rst stage due to drug inac vity. 46 Twelve pa ents (44.4%) had stable disease as their best response. Grade 3 and 4 adverse events occurring in more than 10% of treated patients were uncommon and were limited to neutropenia (22.2%), thrombocytopenia (14.8%), and vomi ng (11.1%). Unfortunately, single-agent belinostat failed to show clinical responses in a cohort of patients with platinumresistant epithelial ovarian cancer, despite the accumula on of acetylated histones H3 and H4 in peripheral blood mononuclear cells. 47 In another study, once again conducted in the pla numresistant se ng, belinostat was used in combina on with carbopla n and paclitaxel. 48 A total of 35 women were treated in the phase II expansion cohort with 1000 mg/m 2 of belinostat daily for 5 days with carbopla n area under the curve of 5 plus 175 mg/m 2 of paclitaxel given on day 3 of a 21-day cycle. Once again, in a heavily treated cohort (54% with more than two prior pla num-based combina ons), there were three complete responses and 12 par al response, for an ORR of 43% (95% CI, 26%-61%). 48 The most frequent treatment-related adverse events in the trial were nausea (83%), fa gue (74%), vomi ng (63%), alopecia (57%), and diarrhea (37%). The discrepant drug ac vity seen in these two trials may be related to trial design and eligibility criteria, or alterna vely the incorpora on of paclitaxel in the la er, which has been shown to be synergis c with HDAC inhibi on. 49 Furthermore, both studies failed to iden fy biomarkers predic ve of response.
Analogous to endometrioid endometrial cancer, endometriosis-associated ovarian cancers, including clear cell and endometrioid histologic types, frequently harbor ARID1A muta ons. In a pivotal study, Wiegand and colleagues implicated ARID1A as a tumor suppressor gene frequently disrupted in ovarian endometrioid and clear cell carcinomas. 50 In a cohort of 152 cancer specimens, ARID1A muta ons were iden fi ed in 46% of clear cell cancers and 30% of the endometrioid ovarian carcinoma specimens (Table 2) . 30, 31, [51] [52] [53] [54] Importantly, none of the 76 high-grade serous cancer specimens exhibited an iden fi able muta on. 50 Furthermore, ARID1A muta ons and lack of BAF250a protein expression were iden fi ed in neighboring, con guous preneoplas c atypical endometrio c lesions, establishing ARID1A muta on as a poten al early event in the transforma on of endometriosis into cancer. 50 To capitalize on these fi ndings, clinical trialists are looking to examine the effi cacy of tazemetostat as single-agent treatment in pa ents with measurable, recurrent clear cell and endometrioid ovarian cancer.
CERVICAL CANCER
A er the iden fi ca on of cispla n as an eff ec ve drug in the treatment of cervical cancer, many eff ec ve singleagent and combination drug regimens were identified with improved response rates, but no overall survival advantage. [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] The poor oncologic outcome in this pa ent popula on has driven the explora on of novel treatment paradigms. 72 Most recently, GOG protocol 240 was completed, illustra ng a signifi cant improvement in overall survival (17 vs. 13.3 months; p = .007) with the incorpora on of the an angiogenic agent bevacizumab to a chemotherapy backbone, without a deteriora on in quality of life. [73] [74] [75] [76] This milestone represented the fi rst me a targeted agent resulted in an overall survival advantage in the gynecologic cancer arena, resul ng in FDA approval of bevacizumab in the treatment of advanced-stage or recurrent cervical cancer. 77 Cervical cancer is unique among gynecologic cancers because several risk factors are well established, and the causa ve agent, human papillomavirus (HPV), is known. This was confi rmed in the molecular characteriza on of cervical cancer, where 95% specimens were found to be HPV posi ve. High-risk HPV infec on alone is not suffi cient for malignant transforma on, and it is hypothesized the alternate gene c and epigenetic factors are required for carcinogenesis. 78 The most extensively studied epigenetic changes in cervical carcinogenesis include DNA methyla on and histone modifi ca on.
Principal targets of methyla on include the p16 protein, a cyclin-dependent kinase inhibitor, which tradi onally funcons as a tumor suppressor. Following HPV infec on, early p16 inac va on has been iden fi ed, with progressive methyla on in more advanced tumors. 79 In addi on to the p16 tumor suppressor, fragile his dine triad gene (FHIT), cyclin A1 (CCNA1), DAPK1, and Ras-associated domain family 1 isoform A (RASSf1A) are targets of DNA promotor methylaon and transcrip onal repression. 79 HPV-related promoter hypermethyla on has also been iden fi ed in genes related to cellular diff eren a on, prolifera on, adhesion, and cell signaling (Sidebar.). The contribution of histone modification has also been evaluated, with increased expression of HDACs in cervical carcinoma. 80 Histone deacetylation results in compact chromatic and transcriptional repression of target genes. In cervical cancer HeLa cell lines, the Wnt antagonist DICKKOPF-1 is downregulated as a result of histone deacetylation, resulting in canonical Wnt pathway activation. 81 Parenthetically, in an alternate cell line, SNU-703, DICKKOPF-1 silencing was mediated via promotor hypermethyla on.
SIDEBAR. Epigene c Targe ng of Tumor Suppressor Genes via Promoter Hypermethyla on in Cervical Cancer
To date, only hydralazine, an an hypertensive and DNA methyla on inhibitor, has been examined in pa ents with cervical cancer. In a small phase I, dose-escala on study, hydralazine at doses between 50 and 150 mg/d was well tolerated and eff ec ve in the demethyla on and reac va on of tumor suppressor genes, without aff ec ng global DNA methyla on.
82
CONCLUSION
The role of epigene c drugs in the treatment of advancedstage or recurrent ovarian, endometrial, and cervical cancer remains unclear. Despite substan al preclinical ra onale, limited response rates have been observed to date. The interplay between the genome and epigenome in cancer progression is undoubtedly complex and mul factorial, with both environmental and heritable components. Furthermore, the rela ve contribu on of DNA methyla on/hypomethyla on, histone modifi ca on, and miRNA expression on gynecologic cancer genesis con nues to be debated.
Ul mately, targeted therapeu cs and combined approaches will require identification of predictive biomarkers to enrich for pa ent popula ons more likely to respond to tailored interven ons. This may maximize therapeu c benefi t, while limi ng toxicity, given the poten al off -target eff ects of this drug class. 
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